Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
NCT ID: NCT04365868
Last Updated: 2025-12-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
357 participants
INTERVENTIONAL
2020-06-22
2025-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
NCT02158182
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
NCT00366795
Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices
NCT02583698
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
NCT04816916
Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension
NCT01456286
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
belapectin 2 mg/kg lean body mass (LBM)
Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)
Phase 3: The patient will be switched to the optimal dose
belapectin
intravenous
belapectin 4 mg/kg lean body mass (LBM)
Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)
Phase 3: The patient will be switched to the optimal dose
belapectin
intravenous
Placebo
Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)
Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)
Placebo
intravenous
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
belapectin
intravenous
Placebo
intravenous
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Is male or female, ≥ 18 and ≤ 75 years of age at the time of Screening.
2. Is willing and able to provide written informed consent prior to the initiation of any study-specific procedures.
3. Has evidence of portal hypertension, with either one of the following:
1. platelet count \<150,000/mm3
OR
2. documented hepatic venous pressure gradient (HVPG) measurement \>6 mmHg
OR
3. at least two of the following:
* spleen size ≥14 cm (documented by ultrasound, MRI, or CT scan)
* abdominal collateral circulation (documented by ultrasound, MRI, or CT scan or physical examination, ie, caput medusae)
* documented liver transient elastography (eg, FibroScan) ≥20 kilopascals (kPa).
* aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \>1.
4. Has a history confirming nonalcoholic steatohepatitis (NASH) cirrhosis, with at least one of the following:
* There is a historical liver biopsy showing cirrhosis with steatohepatitis. There is no evidence for a competing etiology for the cirrhosis.
* There is a historical liver biopsy showing steatohepatitis, and there is evidence of cirrhosis from clinical or imaging data or a second liver biopsy showing cirrhosis without all features of NASH (as the histological NASH lesions may have burnt out). There is no evidence for a competing etiology. There is at least 1 co-existing metabolic comorbidity at Screening: obesity (with either body mass index \[BMI\] ≥30 kg/m2 or waist circumference ≥102 cm \[40 in, men\] or ≥88 cm \[35 in, women\], or by ethnically appropriate cutpoints); hypertension (either on anti hypertensive drug therapy for at least 1 year or systolic/diastolic blood pressure (BP) \>140/80 mm Hg); Type 2 diabetes (glycated hemoglobin \[HbA1c\] ≥6.5%, or on anti-diabetic medication for at least 1 year); or dyslipidemia (triglycerides ≥150 mg/dL or on drug therapy for hypertriglyceridemia for at least 6 months; high-density lipoprotein cholesterol ≤40 mg/dL \[men\] or ≤50 mg/dL \[women\]) to corroborate a diagnosis of nonalcoholic fatty liver disease (NAFLD).
* There is a historical liver biopsy showing cirrhosis with steatosis but not steatohepatitis. There is no evidence for a competing etiology. There are at least 2 co-existing (or history of) metabolic comorbidities (with obesity or diabetes being one of them) to corroborate a diagnosis of NAFLD.
* There is a historical liver biopsy showing steatosis but now with cirrhosis either by clinical examination, imaging, or biopsy. If there is a current biopsy, it does not show evidence of steatosis or steatohepatitis as histological lesions may have burned out. There is no evidence for a competing etiology. There are at least 2 co existing (or history of) metabolic comorbidities (with obesity or diabetes being one of them) to corroborate a diagnosis of NAFLD.
* Patient with cirrhosis with current or previous imaging showing steatosis. There is no liver histology available. There is no evidence for a competing etiology. There are at least two co-existing or history of metabolic comorbidities with obesity or diabetes being one of them to corroborate a diagnosis of NAFLD.
* For patients not meeting the above mentioned criteria, a screening liver biopsy is necessary.
Note: All liver biopsy blocks and/or slides for eligibility assessments (including those from historical biopsies) will be reviewed by the central study pathologist while the subject is in Screening. Results from the central study pathologist must be available before the subject is randomized.
5. Absence of hepatocellular carcinoma (HCC) by valid imaging (eg, ultrasound, CT scan, or MRI) within 6 months prior to randomization. If no such imaging result is available, then ultrasound imaging should be performed as part of standard of care.
6. Patients with diabetes mellitus can be enrolled, if they are adequately controlled on a stable dose or doses of antidiabetic medication(s) for at least 3 months before Screening, and their screening HbA1c is ≤9.5%.
7. Patients on vitamin E or pioglitazone can be enrolled if they are on a stable dose and regimen for at least 3 months before screening, and the dose is expected to be held constant during the trial.
8. Patients on a statin can be enrolled if they are on a stable regimen for at least 3 months before Screening, and expected to be held stable during the trial.
9. Is not pregnant and must have a negative serum pregnancy test result prior to randomization.
10. Is of non-childbearing potential or if a fertile man or woman participating in heterosexual relations, agrees to use two acceptable means of contraception (ie, 2 effective methods of contraception, one of which must be a physical barrier method \[eg, male or female condom, diaphragm\] when combined with a highly effective method of contraception \[ie, a method with a failure rate of \<1% per year when used consistently and correctly\]) throughout his/her participation in this study and for 90 days after discontinuation of study treatment.
Highly effective forms of contraception include:
* combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (such as oral, intravaginal, transdermal) methods
* progestogen-only hormonal contraception associated with inhibition of ovulation (such as oral, injectable, implantable)
* hormone-releasing intrauterine system (IUS)
* intrauterine device (IUD)
* bilateral tubal occlusion
* a vasectomized partner, provided that partner is the sole sexual partner of the women of childbearing potential trial participant and that the vasectomized partner has received medical assessment of the surgical success
* sexual abstinence (ie, a refraining from heterosexual intercourse during the entire period of the clinical trial, if it is the preferred and usual lifestyle of the subject).
Surgically sterile males and females are not required to use contraception provided they have been considered surgically sterile for at least 6 months. Surgical sterility includes history of surgically successful vasectomy, hysterectomy, or bilateral salpingo-oophorectomy. Postmenopausal women who have been amenorrheic for at least 2 years at the time of Screening will be considered sterile.
11. If a lactating woman, agrees to discontinue nursing before the start of study treatment and refrain from nursing until 90 days after the last dose of study treatment.
12. If a man, agrees to refrain from sperm donation throughout the study period and for a period of 90 days following the last dose of investigational medicinal product (IMP). Female subjects may not begin a cycle of ova donation or harvest throughout the study period and for a period of 90 days following the last dose of IMP.
Exclusion Criteria
1. Presence of esophageal, gastroesophageal, or isolated gastric varices, based on an upper gastrointestinal (GI) esophagogastroduodenoscopy (EGD) exam conducted during Screening. Patients with portal hypertensive gastropathy could be enrolled.
2. History of hepatic cirrhosis decompensation including any episode of variceal bleeding, ascites not controlled by medication, spontaneous bacterial peritonitis or overt hepatic encephalopathy (West Haven grade ≥2 as assessed by the principal investigator), OR develops signs of hepatic cirrhosis decompensation during Screening.
3. Known or suspected abuse of alcohol (\>20 g/day for women or \>30 g/day for men \[on average per day\]), as per medical history. Significant alcohol consumption is defined as more than 20 grams per day in females and more than 30 grams per day in males. On average, a standard drink in the United States is considered to be 14 grams of alcohol, equivalent to 12 fluid ounces of regular beer (5% alcohol), 5 fluid ounces of table wine (12% alcohol), or 1.5 fluid ounces of 80 proof spirits (40% alcohol).
4. Alcohol dependence (ie, a score \>8 on the Alcohol Use Disorders Identification Test)
5. Narcotics or any other drug abuse or dependence in the last 5 years
6. Prior trans-jugular intrahepatic portal-systemic (TIPS) shunt procedure
7. Documented causes of liver disease other than NASH, including but not restricted to:
* Viral hepatitis, unless eradicated at least 3 years prior to Screening
* acute hepatitis A infection (presence of hepatitis A immunoglobulin M \[IgM\] at Screening)
* positive hepatitis B surface antigen
* positive hepatitis C virus (HCV) ribonucleic acid (to be performed prior to randomization in case of positive HCV antibody)
* Documented drug-induced liver disease
* Alcoholic liver disease
* Autoimmune hepatitis
* Wilson's disease
* Hemochromatosis
* Primary biliary cholangitis
* Primary sclerosing cholangitis
* Genetic hemochromatosis
* History or planned liver transplantation
* Alpha-1 antitrypsin deficiency
8. History of human immunodeficiency virus (HIV), or positive HIV test at Screening
9. Any of the following test or score:
* serum alanine aminotransferase (ALT) \> 5 × upper limit of normal (ULN)\*
* serum aspartate aminotransferase (AST) \> 5 × ULN\*
\*Screening values will be obtained at Screening Visit 1 (SV1) and Screening Visit 2(SV2) (which will be separated by 2 to 4 weeks). A second screening value that is \>50% higher than the first value should prompt re-evaluation of the severity of the underlying liver disease and eligibility for this trial. If a transaminase level at SV2 is \>33% different from the level at SV1, then additional measurements should be performed at Screening Visit 3 (SV3). In such cases, the baseline transaminase levels will be established for subjects using the mean value of 4 evaluations \[ie, at SV1, SV2, SV3, and Baseline (ie, pre-dose during Visit 1)\].
* serum alkaline phosphatase (ALP) \> 2 × ULN
* mean platelet count \< 50,000/mm3
* total bilirubin ≥ 2.0 mg/dL (subjects with a documented history of Gilbert's syndrome can be enrolled if the direct bilirubin is within normal reference range)
* model for end-stage liver disease (MELD) score ≥12
* Child-Turcotte-Pugh (CTP) Score ≥7 Note: Following Phase 2b, subjects with CTP scores ≥7 may be enrolled if recommended\* by the Data Safety Monitoring Board (DSMB) and approved by the Trial Steering Committee (TSC), based on the planned interim analysis (IA). \[\*based on DSMB review of preliminary results from a separate hepatic impairment clinical trial (Study GT-032) which is assessing belapectin safety and pharmacokinetic (PK) in cirrhotic subjects with CTP scores ≥7.
* estimated glomerular filtration rate \< 45 mL/min\* \*Note: per Modification of Diet in Renal Disease algorithm
10. Taking an angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, or β-1 selective adrenergic receptor inhibitor, unless on a stable regimen for at least 3 months prior to Screening and no changes in the regimen are anticipated during the study. Subjects taking a non-selective beta blocker are not eligible to be enrolled (Investigators are encouraged to substitute another medication, if clinically warranted).
11. History of major surgery during Screening.
12. History of a solid organ transplant requiring immunosuppressive therapy.
13. History of bariatric surgery within 1 year of randomization, or plan to undergo bariatric surgery during the study.
14. Has positive screening test for illicit drugs of abuse at Screening.
15. Has participated in an investigational new drug study within 30 days or 5 half-lives whichever is longer, prior to randomization.
16. Has a history of malignancy within 5 years of randomization, except for basal cell carcinoma, squamous cell carcinoma, and adequately treated in situ uterine cervical cancer.
17. Has clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring intervention (eg, pacemaker/ablation) or Grade II or greater peripheral vascular disease.
18. Has a history of clinically significant hematologic, renal, hepatic, pulmonary, neurological, psychiatric, gastrointestinal, systemic inflammatory, metabolic or endocrine disorder or any other condition that, in the opinion of the Investigator, renders the subject a poor candidate for inclusion into the study.
19. Has known allergies to the IMP or any of its excipients.
20. Has previously received belapectin within 6 months of randomization.
21. Is an employee or family member of the Investigator or study center personnel.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Galectin Therapeutics Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khurram Jamil, M.D.
Role: STUDY_DIRECTOR
Galectin Therapeutics Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Digestive Health Specialists
Dothan, Alabama, United States
The Institute for Liver Health
Chandler, Arizona, United States
Arizona Liver Health - Glendale
Glendale, Arizona, United States
Institute for Liver Health - Tucson
Tucson, Arizona, United States
Liver Wellness Center - Little Rock
Little Rock, Arkansas, United States
Hope Clinical Research, Inc.
Canoga Park, California, United States
Southern California GI & Liver Centers
Coronado, California, United States
University of California San Diego Medical Center -La Jolla Multi-Specialty Clinics- Perlman Offices
La Jolla, California, United States
Om Research LLC
Lancaster, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
inSite Digestive Health Care - Orange
Orange, California, United States
California Liver Research Institute
Pasadena, California, United States
Inland Empire Liver Foundation
Rialto, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Peak Gastroenterology Associates
Colorado Springs, Colorado, United States
Integrity Clinical Research, LLC (ICR SITES) - Doral
Doral, Florida, United States
Nature Coast Clinical Research, LLC
Inverness, Florida, United States
Mayo Clinic Hospital - Florida
Jacksonville, Florida, United States
Florida Research Institute
Lakewood Rch, Florida, United States
ClinCloud LLC
Maitland, Florida, United States
Advanced Pharma CR, LLC
Miami, Florida, United States
Genoma Research Group, Inc.
Miami, Florida, United States
Sensible Healthcare
Ocoee, Florida, United States
Guardian Angel Health Services, Inc.
Tampa, Florida, United States
Florida Medical Center & Research
Zephyrhills, Florida, United States
Digestive Healthcare of Georgia, P.C.
Atlanta, Georgia, United States
Gastroenterology Associates of Central Georgia, LLC
Macon, Georgia, United States
Gastrointestinal Specialists of Georgia, PC
Marietta, Georgia, United States
Loyola University Health System
Maywood, Illinois, United States
IU Health University Hospital
Indianapolis, Indiana, United States
Michiana Gastroenterology, Inc.
South Bend, Indiana, United States
Kansas Medical Clinic PA
Topeka, Kansas, United States
University of Louisville Physicians - Cardiovascular Medicine Physicians Outpatient Center
Louisville, Kentucky, United States
Tandem Clinical Research, LLC
Marrero, Louisiana, United States
Tulane Cancer Center
New Orleans, Louisiana, United States
Mercy Medical Center - The Institute for Digestive Health and Liver Disease
Baltimore, Maryland, United States
Tufts Medical Center
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Henry Ford Health System - Hemophilia and Thrombosis Treatment Center
Detroit, Michigan, United States
Gastroenterology Associates of Western Michigan
Wyoming, Michigan, United States
Southern Therapy and Advanced Research (STAR) - Jackson
Jackson, Mississippi, United States
Kansas City Research Institute
Kansas City, Missouri, United States
Excel Clinical Research - Las Vegas
Las Vegas, Nevada, United States
Mount Sinai Beth Israel
New York, New York, United States
NYU Langone Medical Center
New York, New York, United States
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
UNC-Chapel Hill School of Medicine
Chapel Hill, North Carolina, United States
Cumberland Research Associates, LLC
Fayetteville, North Carolina, United States
Lucas Research
Morehead City, North Carolina, United States
Consultants for Clinical Research
Cincinnati, Ohio, United States
University of Cincinnati Physicians Company, LLC
Cincinnati, Ohio, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
The Jefferson Digestive Health Institute - Thomas Jefferson University
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center (UPMC) - The Center for Liver Diseases
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina (MUSC)
Charleston, South Carolina, United States
Galen Medical Group - Ziegler Plaza
Chattanooga, Tennessee, United States
University Diabetes & Endocrine Consultants
Chattanooga, Tennessee, United States
Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park
Germantown, Tennessee, United States
Associates in Gastroenterology
Hermitage, Tennessee, United States
East Tennessee Research Institute - Gastrointestinal Associates of Northeast Tennessee, P.C.
Johnson City, Tennessee, United States
Texas Clinical Research Institute, LLC
Arlington, Texas, United States
Liver Specialists of Texas
Austin, Texas, United States
Methodist Transplant Physicians
Dallas, Texas, United States
Texoma Liver Center PLLC. - Denison
Denison, Texas, United States
South Texas Research Institute
Edinburg, Texas, United States
Baylor College of Medicine - Baylor Clinic - Abdominal Transplant & Liver Disease Clinic
Houston, Texas, United States
Pioneer Research Solutions Inc - Houston - Stancliff Rd
Houston, Texas, United States
The Texas Liver Institute, Inc.
San Antonio, Texas, United States
Pinnacle Clinical Research
San Antonio, Texas, United States
Impact Research Institute
Waco, Texas, United States
University of Utah Health Care - UUHC - Kidney & Liver Clinic
Salt Lake City, Utah, United States
University of Virginia School of Medicine
Charlottesville, Virginia, United States
Gastroenterology Associates of Fredericksburg
Fredericksburg, Virginia, United States
Bon Secours Liver Institute of Virginia - Newport News
Newport News, Virginia, United States
Bon Secours Liver Institute of Virginia - Richmond
Richmond, Virginia, United States
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia, United States
Velocity Clinical Research, Spokane
Spokane, Washington, United States
Hospital Italiano de Buenos Aires
Buenos Aires, ARG, Argentina
Hospital Británico de Buenos Aires
Buenos Aires, ARG, Argentina
Centro de Investigaciones Metabólicas (CINME)
Capital Federal, ARG, Argentina
Nepean Hospital
Kingswood, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Monash Medical Centre Clayton
Clayton, Victoria, Australia
Fiona Stanley Hospital
Murdoch, Western Australia, Australia
Antwerp University Hospital
Edegem, Antwerpen, Belgium
Clinique Universitaire De Bruxelles Hôpital Erasme VZW
Brussels, BEL, Belgium
AZ Maria Middelares
Ghent, VOV, Belgium
Universitair Ziekenhuis Gent
Ghent, VOV, Belgium
Groupe sante CHC - Clinique du MontLegia
Liège, WLG, Belgium
University of Calgary - Heritage Medical Research Clinic - Foothills Hospital Center
Calgary, Alberta, Canada
Pacific Gastroenterology Associates
Vancouver, British Columbia, Canada
Brampton Civic Hospital
Brampton, Ontario, Canada
Toronto Liver Centre
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Hospital de La Serena
La Serena, CHL, Chile
Clínica Universidad de los Andes
Santiago, CHL, Chile
Centro de Investigaciones Clinicas Vina del Mar
Viña del Mar, CHL, Chile
Hospital Clínico Universidad de Chile
Santiago, , Chile
Centre Hospitalier Universitaire d'Amiens
Amiens, , France
Hôpital Avicenne
Bobigny, , France
CHU Hôpital Henri Mondor
Créteil, , France
CHU de Grenoble
Grenoble, , France
Hôpital de la Croix-Rousse
Lyon, , France
CHRU Montpellier - Saint Eloi
Montpellier, , France
CHU Nancy - Hôpital Brabois
Nancy, , France
CHU de Nice - L'Archet
Nice, , France
Hôpital Cochin
Paris, , France
Hôpitaux Universitaires de Strasbourg - Hôpital Civil
Strasbourg, , France
Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
Mainz, Rhineland-Palatinate, Germany
EUGASTRO GmbH
Leipzig, Saxony, Germany
Goethe-Universität Frankfurt am Main
Frankfurt am Main, , Germany
Soroka Medical Center
Beersheba, , Israel
Rambam Medical Center
Haifa, , Israel
Carmel Medical Center
Haifa, , Israel
Hadassah Ein Karem Hospital
Jerusalem, , Israel
Holy Family Hospital
Nazareth, , Israel
Rabin Medical Center - Beilinson Hospital
Petah Tikva, , Israel
The Chaim Sheba Medical Center - The Center for Liver Diseases
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
CICPA Centro de Investigación Clinica del Pacifico
Acapulco de Juárez, Guerrero, Mexico
Centro de Investigacion Medico Biologica y Terapia Avanzada SC
Guadalajara, Jalisco, Mexico
Investigacion Biomedica para el desarrollo de farmacos SA de CV
Zapopan, Jalisco, Mexico
Investigacion Biomedica para el desarrollo de farmacos SA de CV
Benito Juárez, Mexico City, Mexico
CEMDEC SA de CV Centro Mexicano de Desarrollo de Estudios Clinicos
Cuauhtémoc, Mexico City, Mexico
Centro Especializado en Diabetes, Obesidad y Pevencion de enfermedades Cadiovasculares SC.
Miguel Hidalgo, Mexico City, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez Servicio de Gastroenterología
Monterrey, Nuevo León, Mexico
Oaxaca Site Management Organization SC.
Oaxaca City, Oaxaca, Mexico
Consultorio Medico
Ciudad de Mexico, State of Mexico, Mexico
Medical Care and Research SA de CV
Mérida, Yucatán, Mexico
Centro de Investigación Medica de Aguascalientes
Aguascalientes, , Mexico
MEDIVEST Centro de Investigacion integral
Chihuahua City, , Mexico
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, , Mexico
SP CSK im Prof. Kornela Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach
Katowice, Silesian Voivodeship, Poland
ID Clinic
Mysłowice, Silesian Voivodeship, Poland
Medyczny Katedra i Klinika Chorób Zakaźnych, Chorób Wątroby i Nabytych Niedoborów Odpornościowych
Wroclaw, , Poland
Medical University of Lodz
Lodz, Łódź Voivodeship, Poland
Fundacion de Investigacion de Diego
San Juan, , Puerto Rico
Hanyang University Seoul Hospital
Seoul, KOR, South Korea
Yonsei University, Wonju Severance Christian Hospital
Seoul, KOR, South Korea
Yonsei University, Wonju Severance Christian Hospital
Wŏnju, KOR, South Korea
Digestive Research Alliance of Michiana, LLC
Incheon, , South Korea
Hospital Universitario 12 de Octubre
Madrid, ESP, Spain
Hospital del Mar Research Institute
Barcelona, , Spain
Hospital Universitario Ramón y Cajal
Madrid, , Spain
Hospital Universitario La Paz
Madrid, , Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, , Spain
Complexo Hospitalario Universitario de Pontevedra
Pontevedra, , Spain
Hospital Universitario Marqués de Valdecilla
Santander, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
King's College Hospital NHS Foundation Trust
London, GBR, United Kingdom
The University of Nottingham - Nottingham Digestive Diseases Centre Biomedical Research Unit
Nottingham, NGM, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GT-031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.